# A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

> **NCT06315491** · PHASE2 · RECRUITING · sponsor: **Cybrexa Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Refractory Ovarian Carcinoma

## Interventions

- **DRUG:** CBX-12

## Key facts

- **NCT ID:** NCT06315491
- **Lead sponsor:** Cybrexa Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315491, "A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06315491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*